Oestrogen receptor beta: what it means for patients with breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15003201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Receptors, Estrogen